Memphasys Transitions to Revenue Growth with Strong Commercial Momentum
Memphasys Limited (ASX: MEM) delivered a significant milestone in the March 2026 quarter, successfully shifting into a revenue-generating phase. The company recorded quarterly revenue exceeding AU$100,000, indicating early traction from the commercial rollout of its Felix System across international markets.
The business secured more than AU$1.4 million in long-term contracted revenue across Europe and the Middle East, supported by repeat product orders that confirm growing clinical usage and a developing recurring revenue stream. Key regulatory approvals in major regions, including Europe and Australia, have strengthened its market access, while progress in India presents additional expansion potential.
At the same time, the company improved operational efficiency by reducing costs and reallocating resources toward commercialisation and manufacturing. Overall, Memphasys is now positioned to scale its operations, increase clinic adoption, and build a sustainable revenue base in the global reproductive biotechnology sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Memphasys Transitions to Revenue Growth with Strong Commercial Momentum
Memphasys Limited (ASX: MEM) delivered a significant milestone in the March 2026 quarter, successfully shifting into a revenue-generating phase. The company recorded quarterly revenue exceeding AU$100,000, indicating early traction from the commercial rollout of its Felix System across international markets.
The business secured more than AU$1.4 million in long-term contracted revenue across Europe and the Middle East, supported by repeat product orders that confirm growing clinical usage and a developing recurring revenue stream. Key regulatory approvals in major regions, including Europe and Australia, have strengthened its market access, while progress in India presents additional expansion potential.
At the same time, the company improved operational efficiency by reducing costs and reallocating resources toward commercialisation and manufacturing. Overall, Memphasys is now positioned to scale its operations, increase clinic adoption, and build a sustainable revenue base in the global reproductive biotechnology sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au